1. Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16
- Author
-
Pierce, John P, Benmarhnia, Tarik, Chen, Ruifeng, White, Martha, Abrams, David B, Ambrose, Bridget K, Blanco, Carlos, Borek, Nicolette, Choi, Kelvin, Coleman, Blair, Compton, Wilson M, Cummings, K Michael, Delnevo, Cristine D, Elton-Marshall, Tara, Goniewicz, Maciej L, Gravely, Shannon, Fong, Geoffrey T, Hatsukami, Dorothy, Henrie, James, Kasza, Karin A, Kealey, Sheila, Kimmel, Heather L, Limpert, Jean, Niaura, Raymond S, Ramôa, Carolina, Sharma, Eva, Silveira, Marushka L, Stanton, Cassandra A, Steinberg, Michael B, Taylor, Ethel, Bansal-Travers, Maansi, Trinidad, Dennis R, Gardner, Lisa D, Hyland, Andrew, Soneji, Samir, and Messer, Karen
- Subjects
Substance Misuse ,Prevention ,Clinical Research ,Tobacco Smoke and Health ,Drug Abuse (NIDA only) ,Cancer ,Tobacco ,6.1 Pharmaceuticals ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Evaluation of treatments and therapeutic interventions ,Prevention of disease and conditions ,and promotion of well-being ,Respiratory ,Good Health and Well Being ,Adolescent ,Adult ,Behavior Therapy ,Cigarette Smoking ,Drug Therapy ,Electronic Nicotine Delivery Systems ,Female ,Humans ,Incidence ,Longitudinal Studies ,Male ,Smoking Cessation ,Time Factors ,Tobacco Use Cessation Devices ,Tobacco Use Disorder ,United States ,Vaping ,Young Adult ,General Science & Technology - Abstract
BackgroundMore smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy.ObjectiveTo assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.DesignCohort study of US sample, with annual follow-up.ParticipantsUS adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443).ExposuresUse of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2.AnalysisPropensity score matching (PSM) of groups using different methods to quit.Outcome measures12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome.ResultsAmong daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products.LimitationsThe frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA.ConclusionAmong US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.
- Published
- 2020